BRPI0519124A2 - composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço - Google Patents
composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇçoInfo
- Publication number
- BRPI0519124A2 BRPI0519124A2 BRPI0519124-6A BRPI0519124A BRPI0519124A2 BR PI0519124 A2 BRPI0519124 A2 BR PI0519124A2 BR PI0519124 A BRPI0519124 A BR PI0519124A BR PI0519124 A2 BRPI0519124 A2 BR PI0519124A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- related diseases
- symptoms
- treating
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
COMPOSTO, MÉTODO PARA TRATAR, PREVENIR OU MELHORAR OBESIDADE E DOENÇAS RELACIONADAS E/OU SINTOMAS DAS MESMAS, COMPOSIÇçO FARMACÊUTICA, USO DE COMPOSTO, E, COMBINAÇçO. A presente invenção refere -se a um composto de fórmula (I) antagonista de hormônio concentrador de melanina; na qual w, R¹, q, p, R², t, Ar¹, L~ 1~, Rü e R^ 4^ são como definidos, ou um sal, solvato, ou enantiômero do mesmo farmaceuticamente aceitável útil no tratamento, na prevenção ou na melhoria de sintomas associados com obesidade e doenças relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63714304P | 2004-12-17 | 2004-12-17 | |
PCT/US2005/045866 WO2006066174A1 (en) | 2004-12-17 | 2005-12-16 | Thiazolopyridinone derivates as mch receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519124A2 true BRPI0519124A2 (pt) | 2008-12-23 |
Family
ID=36123161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519124-6A BRPI0519124A2 (pt) | 2004-12-17 | 2005-12-16 | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço |
Country Status (12)
Country | Link |
---|---|
US (1) | US7902356B2 (pt) |
EP (1) | EP1828207B1 (pt) |
JP (1) | JP5072602B2 (pt) |
CN (1) | CN101080411B (pt) |
AT (1) | ATE446962T1 (pt) |
AU (1) | AU2005316314B2 (pt) |
BR (1) | BRPI0519124A2 (pt) |
CA (1) | CA2589695A1 (pt) |
DE (1) | DE602005017423D1 (pt) |
ES (1) | ES2333243T3 (pt) |
MX (1) | MX2007007227A (pt) |
WO (1) | WO2006066174A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1798221A4 (en) | 2004-10-01 | 2010-04-07 | Banyu Pharma Co Ltd | NITROGENIC HETEROCYCLIC 2-ARYLCARBOXYLENEAMIDE COMPOUND |
US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
JP5198439B2 (ja) * | 2006-06-08 | 2013-05-15 | イーライ リリー アンド カンパニー | 新規なmch受容体アンタゴニスト |
EP2089397B1 (en) * | 2006-12-14 | 2012-08-29 | Eli Lilly & Company | 5- [4- (azetidin-3-yl0xy) -phenyl]-2-phenyl-5h-thiaz0l0 [5,4-c]pyridin-4-0ne derivatives and their use as mch receptor antagonists |
WO2008140239A1 (en) * | 2007-05-11 | 2008-11-20 | Korea Research Institute Of Chemical Technology | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same |
DE102007028925A1 (de) | 2007-06-22 | 2008-12-24 | Saltigo Gmbh | Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden |
US20090076275A1 (en) * | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
JPWO2010024258A1 (ja) | 2008-08-29 | 2012-01-26 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環アゾール誘導体 |
EP2513118B1 (en) | 2009-12-18 | 2013-09-18 | Janssen Pharmaceutica, N.V. | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
BR112012014436A2 (pt) | 2009-12-18 | 2019-09-24 | Janssen Pharmaceutica Nv | tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 |
KR101893751B1 (ko) | 2010-07-16 | 2018-09-03 | 애브비 아일랜드 언리미티드 컴퍼니 | 항바이러스성 화합물의 제조 방법 |
US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
BR112013001138A2 (pt) | 2010-07-16 | 2016-07-05 | Abbvie Inc | ligantes de fosfina para reações catalíticas |
CN102532123B (zh) * | 2010-12-29 | 2016-03-09 | 中国医学科学院药物研究所 | 噻唑-5-甲酰胺化合物、及其制法和药物组合物与用途 |
WO2012109573A1 (en) * | 2011-02-11 | 2012-08-16 | Purdue Research Foundation | Substituted thiazoles for use as antiviral agents |
JP6185979B2 (ja) * | 2012-03-27 | 2017-08-23 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 除草活性及び殺虫活性を有するチアゾロピリジノン類 |
WO2013168759A1 (ja) | 2012-05-10 | 2013-11-14 | 武田薬品工業株式会社 | 芳香環化合物 |
TR201815683T4 (tr) | 2014-01-13 | 2018-11-21 | Aurigene Discovery Tech Ltd | Irak4 inhibitörleri olarak bisiklik heterosiklil türevleri. |
WO2015138280A2 (en) * | 2014-03-10 | 2015-09-17 | Innov17 Llc | Retinoic acid receptor-related orphan receptor modulators and uses thereof |
US20150252022A1 (en) * | 2014-03-10 | 2015-09-10 | Innov17 Llc | Retinoic acid receptor-related orphan receptor modulators and uses thereof |
KR20180025896A (ko) * | 2015-07-15 | 2018-03-09 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak-4 저해제로서 인다졸 및 아자인다졸 화합물 |
KR102646115B1 (ko) * | 2016-03-11 | 2024-03-12 | 에이씨 이뮨 에스에이 | 진단 및 치료를 위한 바이사이클릭 화합물 |
SI3600270T1 (sl) | 2017-03-31 | 2023-10-30 | Aurigene Oncology Limited | Spojine in sestavki za zdravljenje hematoloških motenj |
EP3704108B1 (en) | 2017-10-31 | 2024-04-24 | Curis, Inc. | Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer |
CN109928939A (zh) * | 2019-02-27 | 2019-06-25 | 上海卡洛化学有限公司 | 一种2,2,6,6-四甲基吗啉的制备方法 |
EP4320127A1 (en) | 2021-04-05 | 2024-02-14 | Halia Therapeutics, Inc. | Nek7 inhibitors |
WO2022226182A1 (en) | 2021-04-22 | 2022-10-27 | Halia Therapeutics, Inc. | Nek7 inhibitors |
CN115403456B (zh) * | 2022-09-22 | 2023-11-17 | 成都大学 | 一种合成爱德万甜中间体3-羟基-4-甲氧基苯丙醛的方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0867678A (ja) * | 1993-11-10 | 1996-03-12 | Takeda Chem Ind Ltd | 複素環アミド化合物、その製造法および剤 |
JP2002371059A (ja) * | 2000-05-16 | 2002-12-26 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
US7229986B2 (en) * | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
WO2004052848A1 (en) | 2002-12-11 | 2004-06-24 | Eli Lilly And Company | Novel mch receptor antagonists |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
WO2005047293A1 (en) | 2003-11-07 | 2005-05-26 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
MX2007007226A (es) * | 2004-12-17 | 2007-08-21 | Lilly Co Eli | Antagonistas receptores novedosos de hormona concentradora de melanina (mch). |
EP1987020B1 (en) | 2006-02-15 | 2012-10-03 | Sanofi | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments |
-
2005
- 2005-12-16 AU AU2005316314A patent/AU2005316314B2/en not_active Ceased
- 2005-12-16 JP JP2007546991A patent/JP5072602B2/ja not_active Expired - Fee Related
- 2005-12-16 BR BRPI0519124-6A patent/BRPI0519124A2/pt not_active IP Right Cessation
- 2005-12-16 CN CN2005800431124A patent/CN101080411B/zh not_active Expired - Fee Related
- 2005-12-16 MX MX2007007227A patent/MX2007007227A/es active IP Right Grant
- 2005-12-16 DE DE602005017423T patent/DE602005017423D1/de active Active
- 2005-12-16 US US11/721,079 patent/US7902356B2/en not_active Expired - Fee Related
- 2005-12-16 CA CA002589695A patent/CA2589695A1/en not_active Abandoned
- 2005-12-16 EP EP05854554A patent/EP1828207B1/en not_active Not-in-force
- 2005-12-16 AT AT05854554T patent/ATE446962T1/de not_active IP Right Cessation
- 2005-12-16 ES ES05854554T patent/ES2333243T3/es active Active
- 2005-12-16 WO PCT/US2005/045866 patent/WO2006066174A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
MX2007007227A (es) | 2007-08-21 |
US20090233919A1 (en) | 2009-09-17 |
CA2589695A1 (en) | 2006-06-22 |
EP1828207B1 (en) | 2009-10-28 |
CN101080411A (zh) | 2007-11-28 |
US7902356B2 (en) | 2011-03-08 |
JP2008524250A (ja) | 2008-07-10 |
AU2005316314A1 (en) | 2006-06-22 |
ES2333243T3 (es) | 2010-02-18 |
CN101080411B (zh) | 2011-11-02 |
DE602005017423D1 (de) | 2009-12-10 |
JP5072602B2 (ja) | 2012-11-14 |
EP1828207A1 (en) | 2007-09-05 |
WO2006066174A1 (en) | 2006-06-22 |
AU2005316314B2 (en) | 2011-06-23 |
ATE446962T1 (de) | 2009-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519124A2 (pt) | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço | |
BRPI0517425A (pt) | composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto | |
PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne | |
BR0316948A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
EA200800081A1 (ru) | Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты) | |
DK1933833T3 (da) | Terapi til behandling af overaktiv blære | |
EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
TW200800946A (en) | Substituted piperazines as metabotropic glutamate receptor antagonists | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
BR0113838A (pt) | Derivados de n-fenil-2-pirimidina-amina | |
DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
ATE384058T1 (de) | Thiazolderivate | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
SE0401342D0 (sv) | Therapeutic compounds | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
BRPI0417858A (pt) | composto, composição farmacêutica, e, uso de uma composição farmacêutica | |
MX2009005798A (es) | Recuperacion de apoplejia. | |
BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
UA92009C2 (ru) | Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодия | |
DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
SE0401655D0 (sv) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |